<<Disclaimer: Verify this information before applying it to your situation.>>
Genetically engineered IL-10 producing Lactococcus lactis bacteria
being developed as a probiotic therapy for inflammatory bowel disease
by a Belgium company, Actogenix, http://www.actogenix.com , may
also have potential as a therapy to restore gluten tolerance in celiac
disease patients. The product, known as TopAct IL-10, is currently in
Phase I human trials and is showing positive results for IBD. A new
study in mice shows the product also protects against anaphylaxis
reactions to foods. In addition to genetic modification to produce IL-
10, the Lactococcus lactis has also been modified to survive freeze-
drying, gastric acids, and bile toxicity. A prior study published in Gut
shows recombinant human IL-10 suppresses gliadin specific T cell
activation in ex vivo celiac biopsy cultures. TopAct IL-10 is therefore a
potential therapy for celiac disease.
----------
IL-10-Secreting Microorganism May Prevent Food-Induced Anaphylaxis
By Martha Kerr
"NEW YORK (Reuters Health) May 08 - Mice pretreated with
Lactococcus lactis genetically engineered to produce interleukin-10 (IL-
10) were protected against anaphylaxis when given an oral antigen
challenge, researchers report."
(Free Medscape registration may be required for access.)
< http://www.medscape.com/viewarticle/556225 >
----------
J Allergy Clin Immunol 2007;119:952-959.
Oral administration of an IL-10–secreting Lactococcus lactis strain
prevents food-induced IgE sensitization
Christophe P. Frossard, PhD, Lothar Steidler, PhD, Philippe A.
Eigenmann, MD
< http://www.jacionline.org/article/PIIS0091674906038073/abstract >
----------
Applied and Environmental Microbiology, December 2006, p. 7694-
7700, Vol. 72, No. 12
Intracellular Accumulation of Trehalose Protects Lactococcus lactis from
Freeze-Drying Damage and Bile Toxicity and Increases Gastric Acid
Resistance
Sofie Termont, Klaas Vandenbroucke, Dirk Iserentant, Sabine Neirynck,
Lothar Steidler, Erik Remaut, and Pieter Rottiers
< http://aem.asm.org/cgi/content/abstract/72/12/7694 >
----------
Gut. 2005 Jan;54(1):46-53.
Recombinant human interleukin 10 suppresses gliadin dependent T cell
activation in ex vivo cultured coeliac intestinal mucosa.
Salvati VM, Mazzarella G, Gianfrani C, Levings MK, Stefanile R, De Giulio
B, Iaquinto G, Giardullo N, Auricchio S, Roncarolo MG, Troncone R.
(Free full text available with free BMJ registration.)
< http://gut.bmj.com/cgi/content/abstract/54/1/46 >
* * *
* Please remember some posters may be WHEAT-FREE, but not GLUTEN-FREE *
Archives are at: Http://Listserv.icors.org/SCRIPTS/WA-ICORS.EXE?LIST=CELIAC
|
